Investing.com - ANI Pharma (NASDAQ: ANIP) reported first quarter EPS of $1.21, $0.23 better than the analyst estimate of $0.98. Revenue for the quarter came in at $137.4M versus the consensus estimate of $125.35M.
Guidance
ANI Pharma sees FY 2024 EPS of $4.26-$4.67 versus the analyst consensus of $4.48.
ANI Pharma sees FY 2024 revenue of $520.00M-$542.00M versus the analyst consensus of $535.11M.
ANI Pharma's stock price closed at $65.88. It is up 16.58% in the last 3 months and up 49.90% in the last 12 months.
ANI Pharma saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See ANI Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, ANI Pharma's Financial Health score is "great performance".
Check out ANI Pharma's recent earnings performance, and ANI Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar